106 results
8-K
EX-99.1
PULM
Pulmatrix Inc
28 Mar 24
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
9:05am
, 2022. The increase is related to higher activity under the Cipla Agreement for PUR1900 during the period.
Research and development expenses decreased … Statements of Operations
(in thousands, except share and per share data)
Year Ended
December 31,
Revenues
Operating expenses
Research and development
8-K
EX-99.1
PULM
Pulmatrix Inc
9 Nov 23
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9:05am
revenues recognized in accordance with the Cipla Agreement for PUR1900 during the period.
Research and development expenses decreased approximately $1.3 … data)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
Revenues
Operating expenses
Research and development
General
8-K
EX-99.1
czcl33rtadpmg4u32t
10 Aug 23
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
ltrq25ro ww73w
12 May 23
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
aoq9aqsr pgjkkexl
30 Mar 23
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
9:05am
8-K
EX-99.1
xg572 mm3mszwf
14 Nov 22
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
6:17am
8-K
EX-99.1
y1f74eab9 spma4oth
10 Aug 22
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
9:15am
8-K
EX-99.1
ivgl5 wxjnb7jt
12 May 22
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
9:15am
8-K
EX-99.1
x2phod0
29 Mar 22
Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update
9:15am